Similar Papers

Paper Title
Journal
Date
Author
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients
Giorgio La Nasa ... Carlo Carcassi
Experimental Hematology | VOL. 41
Giorgio La Nasa, et. al.Giorgio La Nasa ... Carlo Carcassi
01 Feb 2013
Increased NK Cells and Decreased CD3+CD8+CD62L+ T Cells in CML Patients Who Sustained Complete Molecular Remission After Discontinuation of Imatinib
Kazuma Ohyashiki ... Taiichi Kyo
Blood | VOL. 118
Kazuma Ohyashiki, et. al.Kazuma Ohyashiki ... Taiichi Kyo
18 Nov 2011
Activation Levels of Natural Killer Cells and CD8+ T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients
Seiichiro Katagiri ... Kazuma Ohyashiki
Blood | VOL. 120
Seiichiro Katagiri, et. al.Seiichiro Katagiri ... Kazuma Ohyashiki
16 Nov 2012
The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis
...
Blood | VOL. 124
, et. al. ...
06 Dec 2014
View more papers

More From: British Journal of Haematology

Paper Title
Journal
Date
Author
First relapse in older adults with multiple myeloma: Creating new pathways in uncharted territory.
Tanya M Wildes
British journal of haematology | VOL. -
Tanya M WildesTanya M Wildes
27 Jan 2025
The ITP diagnostic challenge.
Tomás José González-López
British journal of haematology | VOL. -
Tomás José González-LópezTomás José González-López
27 Jan 2025
'Pseudothrombocytopenia' a contradictory term in patients with normal platelet counts?
Peter Schuff‐Werner
British journal of haematology | VOL. -
Peter Schuff‐WernerPeter Schuff‐Werner
26 Jan 2025
Genetic testing to identify hereditary predispositions to haematological malignancy is critical prior to allogenic haematopoietic cell transplant.
Amra Kajdic ... Paul Liu
British journal of haematology | VOL. -
Amra Kajdic, et. al.Amra Kajdic ... Paul Liu
26 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.